ADMA Biologics (United States)
company in Ramsey, United States
ADMA Nasdaq
SEC CIK 1368514
Follow ADMA Biologics (United States)
Weekly email: filings, results
Revenue, last quarter
$141.1M
+5.1% vs same quarter last year
Net income
$49.9M
+36.9% vs same quarter last year
EPS, diluted
$0.22
+46.7% vs same quarter last year
Operating cash flow
$17.4M
+30.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $510.2M | $146.9M |
| FY24 | $426.5M | $197.7M |
| FY23 | $258.2M | −$28.2M |
| FY22 | $154.1M | −$65.9M |
| FY21 | $80.9M | −$71.7M |
| FY20 | $42.2M | −$75.7M |
| FY19 | $29.3M | −$48.3M |
| FY18 | $17M | −$65.7M |
| FY17 | $22.8M | −$43.8M |
| FY16 | $10.7M | −$19.5M |
| FY15 | $7.2M | −$18M |
| FY14 | $5.9M | −$16.8M |
| FY13 | $3.1M | −$15.5M |
| FY12 | $1.1M | −$7.3M |
| FY11 | $761K | −$5.9M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 57.4% | 37.5% | 28.8% |
| FY24 | 51.5% | 32.6% | 46.4% |
| FY23 | 34.4% | 8.4% | −10.9% |
| FY22 | 22.9% | −25.5% | −42.8% |
| FY21 | 1.4% | −72.1% | −88.5% |
| FY20 | −45.2% | −153.8% | −179.4% |
| FY19 | −34.6% | −141.1% | −164.5% |
| FY18 | −148.4% | −354.9% | −387.1% |
| FY17 | −28.1% | −172.7% | −192.3% |
| FY16 | 40.3% | −162.6% | −183.1% |
| FY15 | 39.9% | −216.1% | −250.4% |
| FY14 | 36.7% | −270.8% | −284.2% |
| FY13 | 34% | −490.4% | −506.2% |
| FY12 | 40.2% | −707.4% | −653% |
| FY11 | 72.7% | −607.5% | −775.7% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $27.8M |
| FY24 | $110.4M |
| FY23 | $4M |
| FY22 | −$73.4M |
| FY21 | −$125.9M |
| FY20 | −$114.7M |
| FY19 | −$80M |
| FY18 | −$64.8M |
| FY17 | −$39.9M |
| FY16 | −$18.3M |
| FY15 | −$15.4M |
| FY14 | −$17M |
| FY13 | −$11.1M |
| FY12 | −$7M |
| FY11 | −$1.4M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $31.9M |
| FY24 | $0 |
| FY23 | $0 |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | $150K |
| FY11 | $0 |
- ADMA Biologics (United States)
- Healthcare median
Show the numbers
| Year | ADMA Biologics (United States) | Healthcare median |
|---|---|---|
| FY25 | 28.8% | −30.6% |
| FY24 | 46.4% | −47% |
| FY23 | −10.9% | −58% |
| FY22 | −42.8% | −80.4% |
| FY21 | −88.5% | −71.8% |
| FY20 | −179.4% | −62.2% |
| FY19 | −164.5% | −46.2% |
| FY18 | −387.1% | −49.6% |
| FY17 | −192.3% | −45.9% |
| FY16 | −183.1% | −36% |
| FY15 | −250.4% | −37.8% |
| FY14 | −284.2% | −35.5% |
| FY13 | −506.2% | −37.1% |
| FY12 | −653% | −29.1% |
| FY11 | −775.7% | −27.9% |